HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.
HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.
复制标题
HMGB1 可能是预测多发性肌炎/皮肌炎伴间质性肺疾病患者预后的生物标志物
DOI：
10.1371/journal.pone.0161436
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Wang G
中科院分区：
文献类型：
--
作者：
Shu X;Peng Q;Lu X;Wang G
目的探讨高迁移率族蛋白B1（HMGB 1）在多发性肌炎（PM）和皮肌炎（DM）合并间质性肺疾病患者中的意义，以及HMGB 1水平能否预测疾病转归。采用ELISA法检测34例PM/DM患者和34例健康对照者血清中HMGB 1水平。PM患者血清HMGB 1水平[12.75 ng/ml（4.34-25.07 ng/ml），p < 0.001]和DM患者血清HMGB 1水平[20.75 ng/ml（3.80-124.88 ng/ml），p < 0.001]显著高于健康对照组[5.64 ng/ml（2.71-8.71 ng/ml）]。值得注意的是，PM/DM伴间质性肺疾病（ILD）患者的平均HMGB 1水平为25.84 ng/ml，显著高于无ILD的PM/DM患者[12.68 ng/ml]（p < 0.05）。受试者工作特征（ROC）曲线分析显示，血清HMGB 1最能区分PM/DM伴ILD与不伴ILD患者的临界值为14.5ng/ml。曲线下面积为0.87±0.05，95%置信区间（CI）为0.77-0.98。HMGB 1临界值诊断胃癌的敏感性为84.6%，特异性为89%。HMGB 1表达水平较高的患者总生存率和无病生存率较低，而HMGB 1表达水平较低的患者生存率较高。多因素分析显示HMGB 1表达是患者生存的预后指标。这些数据支持HMGB 1过表达参与ILD患者PM/DM进展的观点，并与其不良临床结局相关。
To investigate the significance of high mobility group box 1 (HMGB1) levels in polymyositis (PM) and dermatomyositis (DM) patients with interstitial lung disease and whether HMGB1 levels could predict disease outcome. HMGB1 levels were measured in sera from 34 patients with PM/DM and from 34 healthy controls by ELISA. Significantly higher serum levels of HMGB1 were found in patients with PM [12.75 ng/ml (4.34–25.07 ng/ml), p < 0.001] and DM [20.75 ng/ml (3.80–124.88 ng/ml), p < 0.001] than in healthy controls [5.64 ng/ml (2.71–8.71 ng/ml)]. Importantly, the average HMGB1 level in PM/DM patients with interstitial lung disease (ILD) was 25.84 ng/ml, which is significantly higher than that in PM/DM patients without ILD [12.68 ng/ml] (p < 0.05). A receiver operating characteristic (ROC) curve analysis revealed that the serum HMGB1 cutoff value that best discriminated PM/DM patients with ILD from those without ILD was 14.5ng/ml. The area under the curve was 0.87±0.05, and the 95% Confidence interval (CI) was 0.77–0.98. The diagnostic sensitivity and specificity of this serum HMGB1 cutoff level was 84.6% and 89% respectively. Patients with higher levels of HMGB1 expression had lower overall survival rates and disease-free survival rates, whereas patients with lower levels of HMGB1 expression had higher survival rates. Multivariate analysis showed that HMGB1 expression is a prognostic indicator for patient survival. These data support the notion that HMGB1 overexpression is involved in PM/DM progression for patients with ILD and is relative to its poor clinical outcomes.